BridgeMD
PROMOTE
EU CTIS ID: 2024-520351-24-00
What this study is testing
This study will assess the feasibility and safety of a single antiplatelet strategy with a reduced dose of prasugrel 5 mg after percutaneous coronary intervention in acute and chronic coronary syndrome patients.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Acute coronary intervention
- Chronic coronary syndrome
- Successfull PCI (according tot treating physician)
You likely can't join if
- Known allergy or contraindication for prasugrel (including active pathological bleeding, severe liver disease (defined as Child Pugh class C))
- Current indication for oral anticoagulant therapy (OAC)
- Indication for ongoing DAPT (e.g. PCI ≤ 6 months for CCS or ACS ≤ 12 months)
- Pregnancy or breast-feeding women
- Participation in another trial with an investigational drug or device
- Recent or ongoing use of CYP2B6 substrates with a narrow therapeutic window
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.